Galantamine: A review of its use in alzheimer's disease and vascular dementia

International Journal of Clinical Practice

Volumn 57, Issue 3, 2003, Pages 219-223

  Corey Bloom, Jody ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 INHIBITOR; DIGOXIN; DONEPEZIL; ERYTHROMYCIN; GALANTAMINE; KETOCONAZOLE; NICOTINIC RECEPTOR; PAROXETINE; PLACEBO; RIVASTIGMINE; SUXAMETHONIUM; TACRINE; WARFARIN;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS;

EID: 0037397980     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
2. Pendlebury WW, Solomon PR. Alzheimer's disease. Clin Symp 1996; 48: 2-32.
3. Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 35-48.
4. Rockwood K, Wentzel C, Hachinski V et al. Prevalence and outcomes of vascular cognitive impairment. Neurology 2000; 54: 447-451.
5. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-2556.
6. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990; 68: 267-289.
7. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
8. Togashi H, Matsumoto M, Yoshioka M et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117-120.
9. Tanaka K, Ogawa N, Asanuma M et al. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch Int Pharmacodyn Ther 1993; 323: 85-96.
10. Kimura S, Saito H, Minami M et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167-178.
11. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-2276.
12. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165-170.
13. Reminyl® (galantamine hydrobromide) tablets [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, 2001.
14. Szewczyk J, Lewin AH, Carroll FI. An improved synthesis of galanthamine. J Heterocyclic Chem 1988; 25: 1809-1811.
15. Szewczyk J, Wilson JW, Lewin AH, Carroll FI. Facile synthesis of (±), (+)-, and (-)-galanthamine. J Heterocyclic Chem 1995; 32: 195-199.
16. Czollner L, Frantsits W, Küenburg B et al. New kilogram-synthesis of the anti-Alzheimer drug (-)-galanthamine [abstract]. Tetrahedron Lett 1998; 39: 2087-2088.
17. Han S-Y, Mayer SC, Schweiger EJ et al. Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors. Bioorganic Med Chem Lett 1991; 1: 579-580.
18. Shieh W-C, Carlson JA. Asymmetric transformation of either enantiomer of narwedine via total spontaneous resolution process, a concise solution to the synthesis of (-)-galanthamine. J Org Chem 1994; 59: 5463-5465.
19. Bastida J, Viladomat F, Llabrés JM et al. Narcissus nivalis: a new source of galanthamine. Planta Med 1990; 56: 123-124.
20. Viladomat F, Bastida J, Codina C. Narcissus alkaloids, XVII. Obesine, a novel alkaloid from narcissus obesus. J Nat Prod 1992; 55: 804-806.
21. Moraes-Cerdeira RM, Bastos JK, Burandt CL Jr et al. Alkaloid content of different bulb parts of narcissus cv. ice follies. Planta Med 1997; 63: 92-93.
22. Baraka A, Harik S. Reversal of central anticholinergic syndrome by galanthamine. JAMA 1977; 238: 2293-2294.
23. Cozanitis DA. Experiences with galanthamine hydrobromide as curare antagonist. Anaesthetist 1971; 20: 226-229.
24. De Angelis M, Walts LF. Comparison of galanthamine with neostigmine for reversal of d-tubocurarine neuromuscular blockade in man. Anesth Analg 1972; 51: 196-199.
25. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268.
26. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-1449.
27. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-1290.
28. Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 2001; 98: 2089-2094.
29. Bickel U, Thomsen T, Weber W et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420-428.
30. Bores GM, Huger FP, Petko W et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-738.
31. Thomsen T, Kaden B, Fischer JP et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487-492.
32. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553-1558.
33. Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603-605.
34. Greenblatt HM, Kryger G, Lewis T et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS(?) Lett 1999; 463: 321-326.
35. Sweeney JE, Puttfarcken PS, Coyle JT. Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav 1989; 34: 129-137.
36. Thomsen T, Zendeh B, Fischer JP, Kewitz H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41: 139-141.
37. Maelicke A, Samochocki M, Jostock R et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-288.
38. Barnes CA, Meltzer J, Houston F et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000; 99: 17-23.
39. Pereira EF, Alkondon M, Reinhardt S et al. Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 1994; 270: 768-778.
40. Schrattenholz A, Pereira EF, Roth U et al. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996; 49: 1-6.
41. Schröder B, Reinhardt S, Schrattenholz A et al. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor a-polypeptide. J Biol Chem 1994; 269: 10407-10416.
42. Storch A, Schrattenholz A, Cooper JC et al. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists, on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995; 290: 207-219.
43. Pereira EF, Reinhardt-Maelicke S, Schrattenholz A et al. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 1993; 265: 1474-1491.
44. 2 nAChR. Acta Neurol Scand Suppl 2000; 176: 68-73.
45. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. DDT(?) 1996; 1: 53-59.
46. Albuquerque EX, Pereira EF, Mike A et al. Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behav Brain Res 2000; 113: 131-141.
47. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000; 20: 66-75.
48. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11(suppl 1): 11-18.
49. Jones RW, Cooper DM, Haworth J et al. The effect of food on the absorption of galantamine in healthy elderly volunteers [abstract]. Br J Clin Pharmacol 1996; 42: 671P.
50. Wood DM, Ford JM, Wilcock GK, Roberts CJC. Plasma protein binding of galanthamine; a potential agent for the treatment of Alzheimer's disease [abstract]. Eur J Clin Pharmacol 1997; 52(suppl): A161.
51. Bachus R, Bickel U, Thomsen T et al. The O-demethylation of the anti-dementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661-668.
52. Piotrovsky V, Van Peer A, Van Osselaer N et al. Galantamine (Reminyl®) population pharmacokinetics in Alzheimer's patients: modeling and simulations. Poster presented at: European Association for Clinical Pharmacology and Therapeutics; September 12-15, 2001; Odense, Denmark.
53. Wilkinson D, Lilienfeld S, Truyen L. Galantamine improves activities of daily living in patients with Alzheimer's disease: a 3-month placebo-controlled study. Poster presented at: Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000.
54. Rockwood K, Mintzer J, Truyen L et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-595.
55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
56. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44: 2315-2321.
57. Cummings JL, Mega M, Gray K et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
58. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-481.
59. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S33-S39.
60. Doody RS, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: results of a long-term extension trial in Alzheimer's disease [abstract]. Neurology 2001; 56(suppl 3): A456.
61. Mintzer JE, Yuan W, Kershaw P. Efficacy of galantamine in patients with Alzheimer's disease (AD) with previous exposure to cholinesterase inhibitors. Poster presented at: American College of Neuropsychopharmacology; December 10-14, 2000; San Juan, Puerto Rico.
62. Torfs K, Feldman H. 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized placebo-controlled studies. Poster presented at: World Alzheimer Congress; July 9-18, 2000; Washington, DC.